A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used whenever possible to strengthen the evidence base
Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on ...
最新管线布局 据药融云数据(www.pharnexcloud.com)以及安进官网公布的最新产品管线(Pipeline),共有59个在研项目,充分展示了其强大的研发和创新能力。所有在研项目中,血液/肿瘤相关的产品线最为丰富,有28项;其次为炎症相关产品共17项;心脏代谢8项;骨科...
THOUSAND OAKS, Calif.,June 12, 2024/PRNewswire/ --Amgen(NASDAQ:AMGN) today announced the presentation of data across its diverse portfolio and pipeline at theEuropean Alliance of Associations for Rheumatology's(EULAR) 2024Congress,June 12-15inVienna. The 27 abstracts fromAmgen-sponsored a...
Amgen has created a robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illnesses. Amgen Science Podcasts From studying DNA in the lab to working with patients in clinical trials, Amgen scientists are pioneering new approaches to understanding human ...
8.https://www.amgenpipeline.com/ 9.https://www.bloomberg.com/profile/company/AMGN:US 10.https://www.fiercepharma.com/pharma/not-quite-a-year-into-launch-amgen-wants-to-can-its-aimovig-collaboration-novartis-lawsuit 11.https://www.forbes.com/companies/amgen/#3c82d5e56ae3 ...
Additional Analyses Support Eculizumab (a biosimilar candidate to SOLIRIS®) as a Potential Option in Paroxysmal Nocturnal Hemoglobinuria THOUSAND OAKS, Calif.,Dec. 8, 2023/PRNewswire/ --Amgen(NASDAQ:AMGN) today announced the presentation of new data from its blood cancer portfolio and pi...
Amgen has announced it will buy Kai Pharmaceuticals for USdollar315 million. Kai's lead candidate, KAI-4169, is set to begin Phase III trials for treating secondary hyperthyroidism (SHPT) in dialysis patients with chronic kidney disease (CKD), and so could join Amgens cinacalcet (Sensipar/Mim...
Amgen builds secondary hyperparathyroidism pipelineNature Reviews Drug Discovery 11, 579 (2012). doi:10.1038/nrd3791Author: Man Tsuey TseNature Reviews Drug Discovery11, 4 ...doi:10.1038/nrd3768TseMan TsueyNat Rev Drug DiscovNature Reviews Drug Discovery...
A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. Amgen is committed to unlocking the potential of biology for patients...